Results 261 to 270 of about 48,636 (310)

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review. [PDF]

Cureus
Sikkal A, Ouahmane S, El Otmani H, El Moutawakil B, Rafai MA.   +4 more
europepmc   +1 more source

Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas. [PDF]

Mol Cancer Ther
Orozco JJ, Matesan MC, Lundberg SJ, Haaf RL, Miyaoka RS, Fisher DR, Gooley TA, Green DJ, Sandmaier BM, Martin PS, Gopal AK.   +10 more
europepmc   +1 more source

B-cell-driven relapse and anti-CD20 rescue therapy after Alemtuzumab in RRMS: case report and literature review. [PDF]

Front Immunol
Bruno PA, Barone S, Pascarella A, Lanza PL, Tinelli E, Gambardella A, Valentino P.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ofatumumab and Granzyme B as immunotoxin against CD20 antigen

In Silico Pharmacology, 2022
Anti-CD20 antibodies such as ofatumumab has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. In this study, we have designed an immunotoxin composed of Granzyme B and the high affinity variant of Ofatumumab.
Fateme Sefid, Armina Alagheband Bahrami, Zahra Payandeh, Saeed Khalili, Ghasem Azamirad, Seyed Mehdy Kalantar, Maryam Touhidinia   +6 more
openaire   +2 more sources

Expression of CD20-specific chimeric antigen receptor (CD20-CAR) on Jurkat T cellsand evaluation its biological activity

Ministry of Science and Technology, Vietnam, 2022
CD20 is a potential target for immunotherapy treatments of haematological malignancies due to its specific expression and unique biological property. Over the years, many anti-CD20 monoclonal antibodies (mAbs) have been developed, such as Rituximab, Ibritumomab, Tositumomab, etc., and applied in B cells related to cancer treatments.
Nguyen Thanh Thao Vo, Dao Xuan Truc Chu, Dam Kim Tuyen Huynh, Thi Viet Anh Phung, Dang Quan Nguyen   +4 more
openaire   +1 more source

Development of a Mimotope-Based Vaccine Against CD20 Antigen

Protein & Peptide Letters, 2007
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to ...
Meng, Li, Wei, Han, Quiyang, Zhang, Xiaochang, Xue, Zenglu, Wang, Yingqi, Zhang   +5 more
openaire   +2 more sources

CD20: A target antigen for immunotherapy of autoimmune diseases

Autoimmunity Reviews, 2005
This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases.
PEROSA, Federico, FAVOINO, ELVIRA, PRETE, MARCELLA, Caragnano MA, Dammacco F.   +4 more
openaire   +3 more sources

Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

International Journal of Radiation Oncology*Biology*Physics, 2004
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially ...
M Carmen, Hernandez, Susan J, Knox
openaire   +2 more sources

Immunological evaluation of predicted linear B‐cell epitopes of human CD20 antigen

Biotechnology and Applied Biochemistry, 2012
AbstractThe importance of B‐lymphocyte‐restricted differentiation antigen Bp35 (CD20) as a target for immunotherapeutic depletion of B cells is irrefutable. Several anti‐human CD20 (anti‐hCD20) monoclonal antibodies are expressed at different stages of development.
Mahdi Habibi, Anbouhi, Mohsen, Abolhassani, Saeid, Bouzari, Hossein, Khanahmad, Mohammad Reza, Aghasadeghi, Armin, Madadkar-Sobhani, Amir, Amanzadeh, Mahdi, Behdani, Mohammad Ali, Shokrgozar   +8 more
openaire   +2 more sources

Analysis of cis-acting elements present in the CD20/B1 antigen promoter

The Journal of Immunology, 1991
Abstract A genomic clone spanning a large portion of the 5’ untranscribed region of the CD20 gene was isolated. Deletion analysis of subcloned fragments identified several regulatory elements. A major positive cis-acting element was localized between base pairs -290/-186.
P, Rieckmann, G L, Wilson, C, Thevenin, J X, Hong, J H, Kehrl   +4 more
openaire   +2 more sources